Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team.
Vestbo J, Agusti A, Wouters EF, Bakke P, Calverley PM, Celli B, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, MacNee W, Miller B, Rennard SI, Silverman EK, Yates JC, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators. Vestbo J, et al. Among authors: locantore n. Am J Respir Crit Care Med. 2014 May 1;189(9):1022-30. doi: 10.1164/rccm.201311-2006PP. Am J Respir Crit Care Med. 2014. PMID: 24552242 Clinical Trial.
Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD.
Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators. Lomas DA, et al. Among authors: locantore nw. Eur Respir J. 2009 Jul;34(1):95-102. doi: 10.1183/09031936.00156508. Epub 2009 Jan 22. Eur Respir J. 2009. PMID: 19164344 Free article.
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Hurst JR, et al. Among authors: locantore n. N Engl J Med. 2010 Sep 16;363(12):1128-38. doi: 10.1056/NEJMoa0909883. N Engl J Med. 2010. PMID: 20843247 Free article.
Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort.
Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, Rennard SI, Sharafkhaneh A; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Hanania NA, et al. Am J Respir Crit Care Med. 2011 Mar 1;183(5):604-11. doi: 10.1164/rccm.201003-0472OC. Epub 2010 Oct 1. Am J Respir Crit Care Med. 2011. PMID: 20889909
Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease.
Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, Connett JE, Anthonisen NA, Wise RA, Tashkin D, Celli BR, Edwards LD, Locantore N, Macnee W, Tal-Singer R, Lomas DA; ECLIPSE Investigators. Sin DD, et al. Among authors: locantore n. Am J Respir Crit Care Med. 2011 May 1;183(9):1187-92. doi: 10.1164/rccm.201008-1220OC. Epub 2011 Jan 7. Am J Respir Crit Care Med. 2011. PMID: 21216880 Free PMC article. Clinical Trial.
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease.
Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, MacNee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agustí A; ECLIPSE Investigators. Celli BR, et al. Among authors: locantore n. Am J Respir Crit Care Med. 2012 May 15;185(10):1065-72. doi: 10.1164/rccm.201110-1792OC. Epub 2012 Mar 15. Am J Respir Crit Care Med. 2012. PMID: 22427534 Clinical Trial.
Dysregulated adipokine metabolism in chronic obstructive pulmonary disease.
Breyer MK, Rutten EP, Locantore NW, Watkins ML, Miller BE, Wouters EF; ECLIPSE Investigators (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints). Breyer MK, et al. Eur J Clin Invest. 2012 Sep;42(9):983-91. doi: 10.1111/j.1365-2362.2012.02686.x. Epub 2012 Jun 15. Eur J Clin Invest. 2012. PMID: 22703238
Factors associated with change in exacerbation frequency in COPD.
Donaldson GC, Müllerova H, Locantore N, Hurst JR, Calverley PM, Vestbo J, Anzueto A, Wedzicha JA. Donaldson GC, et al. Among authors: locantore n. Respir Res. 2013 Jul 30;14(1):79. doi: 10.1186/1465-9921-14-79. Respir Res. 2013. PMID: 23899210 Free PMC article. Clinical Trial.
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C. Agustí A, et al. Among authors: locantore n. Eur Respir J. 2014 Mar;43(3):763-72. doi: 10.1183/09031936.00054213. Epub 2013 Oct 10. Eur Respir J. 2014. PMID: 24114969 Free article. Clinical Trial.
55 results